<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02984111</url>
  </required_header>
  <id_info>
    <org_study_id>IR.sbmu.ram.rec.1394.292</org_study_id>
    <secondary_id>IRCT2016011621087N1</secondary_id>
    <nct_id>NCT02984111</nct_id>
  </id_info>
  <brief_title>Erythropoietin Effect on Ischemic_ Reperfusion Injury in Coronary Artery Bypass Graft Surgery</brief_title>
  <official_title>Placebo- Controlled,Randomized,Double Blind Trial of Erythropoietin Effect on Ischemic_ Reperfusion Injury in Coronary Artery Bypass Graft Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pooyesh Darou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trail is to assess the safety and therapeutic effects of single EPO&#xD;
      intervention in different times during coronary surgery in changes of inflammatory response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In addition to well-known effect of Erythropoietin (EPO) on erythropoiesis in hypoxic&#xD;
      conditions, some lines of evidence suggest its protective effects against reperfusion injury&#xD;
      in several tissues by its specific receptor.&#xD;
&#xD;
      Preclinical studies have indicated a broad variety of cardioprotective actions for EPO. It&#xD;
      improves cardiac function and exercise capacity in congestive heart failure, angiogenesis,&#xD;
      limit myocardial inflammatory response, cardiac remodeling, infarct size and apoptosis&#xD;
      extension induced by reperfusion injury. Activation of EPO receptor in endothelial and&#xD;
      cardiac cells is suggested to attenuate proinflammatory cytokines production and inflammatory&#xD;
      cells infiltration, and increasing nitric oxide production through possible mechanisms.&#xD;
&#xD;
      Reperfusion injury is unavoidable event during cardiac surgery using cardiopulmonary&#xD;
      bypass.It is associated with inflammation, cell injury and attenuate contractility property.&#xD;
&#xD;
      Although it is an area of concern and many clinical studies have been designed by different&#xD;
      interventions, it remains a major challenge. EPO intervention during heart reperfusion&#xD;
      (surgery/ percutaneous angioplasty) as a new promise of cardioprotection strategy is the main&#xD;
      design of several studies with conflicting results .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Interleukin 6(IL6)</measure>
    <time_frame>Change from baseline until 48 hours after surgery</time_frame>
    <description>Serum IL6(an inflammatory marker) level is measured before operation (base),just after operation,24 hours after operation,48 hours after operation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in YKL-40</measure>
    <time_frame>Change from baseline until 48 hours after surgery</time_frame>
    <description>Chitinase-3-like protein 1 (CHI3L1), also known as YKL-40 is an inflammatory marker.Serum YKL-40 level is measured before operation (base),just after operation,24 hours after operation,48 hours after operation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in pro b-type natriuretic peptide(pro BNP)</measure>
    <time_frame>Change from baseline until 48 hours after surgery</time_frame>
    <description>Serum pro BNP level is measured before operation (base),just after operation,24 hours after operation,48 hours after operation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volume of bleeding</measure>
    <time_frame>During operation until 24 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need to blood transfusion</measure>
    <time_frame>During and after operation, through study completion,an average of one week</time_frame>
    <description>Number of packed cell and fresh frozen plasma that transfused in the period of time that patient is hospitalized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilation time</measure>
    <time_frame>Period of time after surgery that patient has been intubated in ICU,an average of 10 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Myocardial Ischemic Reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20000 IU erythropoietin infusion during aortic cross clamp in 45-60 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20000 IU erythropoietin infusion after induction of anesthesia and before undergoing cardiopulmonary bypass pump in 45-60 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50 ml normal saline infusion during aortic cross clamp in 45-60 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <arm_group_label>control</arm_group_label>
    <other_name>N/S</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erythropoietin</intervention_name>
    <arm_group_label>group A</arm_group_label>
    <arm_group_label>group B</arm_group_label>
    <other_name>epoietin alfa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Revascularization requirement according to angiographic evidence&#xD;
&#xD;
          -  Elective coronary artery bypass graft surgery&#xD;
&#xD;
          -  First time coronary artery bypass graft surgery&#xD;
&#xD;
          -  On-pump coronary artery bypass graft surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of myocardial infarction in the past 3 months&#xD;
&#xD;
          -  Previous myocardial trauma or major surgery in the past 3 months&#xD;
&#xD;
          -  Cr&gt;2mg/dl&#xD;
&#xD;
          -  Receiving streptokinase or previous reperfusion treatments&#xD;
&#xD;
          -  Erythropoietin intake in the recent 6 months&#xD;
&#xD;
          -  Known thromboembolic disorder and malignant disease&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Polycythemia&#xD;
&#xD;
          -  Previous valvular surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahnoosh Foroughi, MD,</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences. Tehran, Iran.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences.</name>
      <address>
        <city>Tehran</city>
        <zip>199873438</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Ziabakhsh-Tabary S, Jalalian R, Mokhtari-Esbuie F, Habibi MR. Echocardiographic Evaluation of the Effects of a Single Bolus of Erythropoietin on Reducing Ischemia-Reperfusion Injuries during Coronary Artery Bypass Graft Surgery; A Randomized, Double-Blind, Placebo-Control Study. Iran J Med Sci. 2014 Mar;39(2):94-101.</citation>
    <PMID>24644377</PMID>
  </reference>
  <reference>
    <citation>Ludman AJ, Yellon DM, Hasleton J, Ariti C, Babu GG, Boston-Griffiths E, Venugopal V, Walker M, Holdright D, Swanton H, Crake T, Brull D, Moon JC, Puranik R, Muthurangu V, Taylor A, Hausenloy DJ. Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial. Heart. 2011 Oct;97(19):1560-5. doi: 10.1136/hrt.2011.223867. Erratum In: Heart. 2011 Nov;97(21):1812. Mutharangu, Vivek [corrected to Muthurangu, Vivek].</citation>
    <PMID>21900585</PMID>
  </reference>
  <reference>
    <citation>Joyeux-Faure M, Durand M, Bedague D, Protar D, Incagnoli P, Paris A, Ribuot C, Levy P, Chavanon O. Evaluation of the effect of one large dose of erythropoietin against cardiac and cerebral ischemic injury occurring during cardiac surgery with cardiopulmonary bypass: a randomized double-blind placebo-controlled pilot study. Fundam Clin Pharmacol. 2012 Dec;26(6):761-70. doi: 10.1111/j.1472-8206.2011.00992.x. Epub 2011 Sep 20.</citation>
    <PMID>21929528</PMID>
  </reference>
  <reference>
    <citation>Najjar SS, Rao SV, Melloni C, Raman SV, Povsic TJ, Melton L, Barsness GW, Prather K, Heitner JF, Kilaru R, Gruberg L, Hasselblad V, Greenbaum AB, Patel M, Kim RJ, Talan M, Ferrucci L, Longo DL, Lakatta EG, Harrington RA; REVEAL Investigators. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA. 2011 May 11;305(18):1863-72. doi: 10.1001/jama.2011.592.</citation>
    <PMID>21558517</PMID>
  </reference>
  <reference>
    <citation>Ott I, Schulz S, Mehilli J, Fichtner S, Hadamitzky M, Hoppe K, Ibrahim T, Martinoff S, Massberg S, Laugwitz KL, Dirschinger J, Schwaiger M, Kastrati A, Schmig A; REVIVAL-3 Study Investigators. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. Circ Cardiovasc Interv. 2010 Oct;3(5):408-13. doi: 10.1161/CIRCINTERVENTIONS.109.904425. Epub 2010 Aug 24.</citation>
    <PMID>20736448</PMID>
  </reference>
  <results_reference>
    <citation>Vilarinho KA, de Oliveira PP, Saad MJ, Eghtesady P, Filho LM, Vieira RW, Petrucci O. Erythropoietin protects the systolic function of neonatal hearts against ischaemia/reperfusion injury. Eur J Cardiothorac Surg. 2013 Jan;43(1):156-62. doi: 10.1093/ejcts/ezs254. Epub 2012 May 7.</citation>
    <PMID>22564802</PMID>
  </results_reference>
  <results_reference>
    <citation>Watson AJ, Gao L, Sun L, Tsun J, Jabbour A, Ru Qiu M, Jansz PC, Hicks M, Macdonald PS. Enhanced preservation of the rat heart after prolonged hypothermic ischemia with erythropoietin-supplemented Celsior solution. J Heart Lung Transplant. 2013 Jun;32(6):633-40. doi: 10.1016/j.healun.2013.03.014.</citation>
    <PMID>23701853</PMID>
  </results_reference>
  <results_reference>
    <citation>Lu MJ, Chen YS, Huang HS, Ma MC. Erythropoietin alleviates post-ischemic injury of rat hearts by attenuating nitrosative stress. Life Sci. 2012 May 22;90(19-20):776-84. doi: 10.1016/j.lfs.2012.04.012. Epub 2012 Apr 12.</citation>
    <PMID>22521289</PMID>
  </results_reference>
  <results_reference>
    <citation>Xu X, Cao Z, Cao B, Li J, Guo L, Que L, Ha T, Chen Q, Li C, Li Y. Carbamylated erythropoietin protects the myocardium from acute ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Surgery. 2009 Sep;146(3):506-14. doi: 10.1016/j.surg.2009.03.022. Epub 2009 Jun 9.</citation>
    <PMID>19715808</PMID>
  </results_reference>
  <results_reference>
    <citation>Prunier F, Biere L, Gilard M, Boschat J, Mouquet F, Bauchart JJ, Charbonnier B, Genee O, Guerin P, Warin-Fresse K, Durand E, Lafont A, Christiaens L, Abi-Khalil W, Delepine S, Benard T, Furber A. Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial. Am Heart J. 2012 Feb;163(2):200-7.e1. doi: 10.1016/j.ahj.2011.11.005.</citation>
    <PMID>22305837</PMID>
  </results_reference>
  <results_reference>
    <citation>Voors AA, Belonje AM, Zijlstra F, Hillege HL, Anker SD, Slart RH, Tio RA, van 't Hof A, Jukema JW, Peels HO, Henriques JP, Ten Berg JM, Vos J, van Gilst WH, van Veldhuisen DJ; HEBE III Investigators. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J. 2010 Nov;31(21):2593-600. doi: 10.1093/eurheartj/ehq304. Epub 2010 Aug 29.</citation>
    <PMID>20802250</PMID>
  </results_reference>
  <results_reference>
    <citation>Momeni M, Liistro G, Baele P, Matta A, Kahn D, Van Dyck M, De Kock M, De Kerchove L, Glineur D, Thiry D, Gregoire A, Jacquet LM, Laarbui F, Watremez C. An increase in endogenous erythropoietin concentrations has no cardioprotective effects in patients undergoing coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2012 Apr;26(2):251-7. doi: 10.1053/j.jvca.2011.07.034. Epub 2011 Oct 5.</citation>
    <PMID>21975293</PMID>
  </results_reference>
  <results_reference>
    <citation>Taniguchi N, Nakamura T, Sawada T, Matsubara K, Furukawa K, Hadase M, Nakahara Y, Nakamura T, Matsubara H. Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebo-controlled study. Circ J. 2010 Nov;74(11):2365-71. doi: 10.1253/circj.cj-10-0267. Epub 2010 Sep 8.</citation>
    <PMID>20834185</PMID>
  </results_reference>
  <results_reference>
    <citation>Bergmann MW, Haufe S, von Knobelsdorff-Brenkenhoff F, Mehling H, Wassmuth R, Munch I, Busjahn A, Schulz-Menger J, Jordan J, Luft FC, Dietz R. A pilot study of chronic, low-dose epoetin-beta following percutaneous coronary intervention suggests safety, feasibility, and efficacy in patients with symptomatic ischaemic heart failure. Eur J Heart Fail. 2011 May;13(5):560-8. doi: 10.1093/eurjhf/hfr002.</citation>
    <PMID>21505058</PMID>
  </results_reference>
  <results_reference>
    <citation>Ferrario M, Arbustini E, Massa M, Rosti V, Marziliano N, Raineri C, Campanelli R, Bertoletti A, De Ferrari GM, Klersy C, Angoli L, Bramucci E, Marinoni B, Ferlini M, Moretti E, Raisaro A, Repetto A, Schwartz PJ, Tavazzi L. High-dose erythropoietin in patients with acute myocardial infarction: a pilot, randomised, placebo-controlled study. Int J Cardiol. 2011 Feb 17;147(1):124-31. doi: 10.1016/j.ijcard.2009.10.028. Epub 2009 Nov 10.</citation>
    <PMID>19906454</PMID>
  </results_reference>
  <results_reference>
    <citation>Poulsen TD, Andersen LW, Steinbruchel D, Gotze JP, Jorgensen OS, Olsen NV. Two large preoperative doses of erythropoietin do not reduce the systemic inflammatory response to cardiac surgery. J Cardiothorac Vasc Anesth. 2009 Jun;23(3):316-23. doi: 10.1053/j.jvca.2008.08.018. Epub 2008 Oct 22.</citation>
    <PMID>18948032</PMID>
  </results_reference>
  <results_reference>
    <citation>Kagaya Y, Asaumi Y, Wang W, Takeda M, Nakano M, Satoh K, Fukumoto Y, Shimokawa H. Current perspectives on protective roles of erythropoietin in cardiovascular system: erythropoietin receptor as a novel therapeutic target. Tohoku J Exp Med. 2012 Jun;227(2):83-91. doi: 10.1620/tjem.227.83.</citation>
    <PMID>22688525</PMID>
  </results_reference>
  <results_reference>
    <citation>Gobe GC, Morais C, Vesey DA, Johnson DW. Use of high-dose erythropoietin for repair after injury: A comparison of outcomes in heart and kidney. J Nephropathol. 2013 Jul;2(3):154-65. doi: 10.12860/JNP.2013.27. Epub 2013 Jul 1.</citation>
    <PMID>24475445</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>November 13, 2016</study_first_submitted>
  <study_first_submitted_qc>December 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2016</study_first_posted>
  <last_update_submitted>October 22, 2017</last_update_submitted>
  <last_update_submitted_qc>October 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Mahnoosh Foroughi</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Coronary artery bypass</keyword>
  <keyword>Erythropoietin</keyword>
  <keyword>Inflammation</keyword>
  <keyword>IL-6</keyword>
  <keyword>Reperfusion injury</keyword>
  <keyword>YKL- 40</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Myocardial Reperfusion Injury</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02984111
org study id: IR.sbmu.ram.rec.1394.292
secondary id: IRCT2016011621087N1
nct id: NCT02984111
lead sponsor: 
collaborator: 
has dmc: Yes
The aim of this trail is to assess the safety and therapeutic effects of single EPO
      intervention in different times during coronary surgery in changes of inflammatory response.
In addition to well-known effect of Erythropoietin (EPO) on erythropoiesis in hypoxic
      conditions, some lines of evidence suggest its protective effects against reperfusion injury
      in several tissues by its specific receptor.

      Preclinical studies have indicated a broad variety of cardioprotective actions for EPO. It
      improves cardiac function and exercise capacity in congestive heart failure, angiogenesis,
      limit myocardial inflammatory response, cardiac remodeling, infarct size and apoptosis
      extension induced by reperfusion injury. Activation of EPO receptor in endothelial and
      cardiac cells is suggested to attenuate proinflammatory cytokines production and inflammatory
      cells infiltration, and increasing nitric oxide production through possible mechanisms.

      Reperfusion injury is unavoidable event during cardiac surgery using cardiopulmonary
      bypass.It is associated with inflammation, cell injury and attenuate contractility property.

      Although it is an area of concern and many clinical studies have been designed by different
      interventions, it remains a major challenge. EPO intervention during heart reperfusion
      (surgery/ percutaneous angioplasty) as a new promise of cardioprotection strategy is the main
      design of several studies with conflicting results .
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Prevention
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
measure: Change in Interleukin 6(IL6)
time frame: Change from baseline until 48 hours after surgery
description: Serum IL6(an inflammatory marker) level is measured before operation (base),just after operation,24 hours after operation,48 hours after operation
measure: Change in YKL-40
time frame: Change from baseline until 48 hours after surgery
description: Chitinase-3-like protein 1 (CHI3L1), also known as YKL-40 is an inflammatory marker.Serum YKL-40 level is measured before operation (base),just after operation,24 hours after operation,48 hours after operation
measure: Change in pro b-type natriuretic peptide(pro BNP)
time frame: Change from baseline until 48 hours after surgery
description: Serum pro BNP level is measured before operation (base),just after operation,24 hours after operation,48 hours after operation
measure: Volume of bleeding
time frame: During operation until 24 hours after surgery
measure: Need to blood transfusion
time frame: During and after operation, through study completion,an average of one week
description: Number of packed cell and fresh frozen plasma that transfused in the period of time that patient is hospitalized.
measure: Ventilation time
time frame: Period of time after surgery that patient has been intubated in ICU,an average of 10 hours
arm group label: group A
arm group type: Active Comparator
description: 20000 IU erythropoietin infusion during aortic cross clamp in 45-60 minutes
arm group label: group B
arm group type: Active Comparator
description: 20000 IU erythropoietin infusion after induction of anesthesia and before undergoing cardiopulmonary bypass pump in 45-60 minutes
arm group label: control
arm group type: Placebo Comparator
description: 50 ml normal saline infusion during aortic cross clamp in 45-60 minutes
intervention type: Drug
intervention name: normal saline
arm group label: control
other name: N/S
intervention type: Drug
intervention name: erythropoietin
arm group label: group A
arm group label: group B
other name: epoietin alfa
criteria: 
gender: All
minimum age: 18 Years
maximum age: 80 Years
healthy volunteers: No
last name: Mahnoosh Foroughi, MD,
role: Principal Investigator
affiliation: Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences. Tehran, Iran.
facility: 
country: Iran, Islamic Republic of
citation: Ziabakhsh-Tabary S, Jalalian R, Mokhtari-Esbuie F, Habibi MR. Echocardiographic Evaluation of the Effects of a Single Bolus of Erythropoietin on Reducing Ischemia-Reperfusion Injuries during Coronary Artery Bypass Graft Surgery; A Randomized, Double-Blind, Placebo-Control Study. Iran J Med Sci. 2014 Mar;39(2):94-101.
PMID: 24644377
citation: Ludman AJ, Yellon DM, Hasleton J, Ariti C, Babu GG, Boston-Griffiths E, Venugopal V, Walker M, Holdright D, Swanton H, Crake T, Brull D, Moon JC, Puranik R, Muthurangu V, Taylor A, Hausenloy DJ. Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial. Heart. 2011 Oct;97(19):1560-5. doi: 10.1136/hrt.2011.223867. Erratum In: Heart. 2011 Nov;97(21):1812. Mutharangu, Vivek [corrected to Muthurangu, Vivek].
PMID: 21900585
citation: Joyeux-Faure M, Durand M, Bedague D, Protar D, Incagnoli P, Paris A, Ribuot C, Levy P, Chavanon O. Evaluation of the effect of one large dose of erythropoietin against cardiac and cerebral ischemic injury occurring during cardiac surgery with cardiopulmonary bypass: a randomized double-blind placebo-controlled pilot study. Fundam Clin Pharmacol. 2012 Dec;26(6):761-70. doi: 10.1111/j.1472-8206.2011.00992.x. Epub 2011 Sep 20.
PMID: 21929528
citation: Najjar SS, Rao SV, Melloni C, Raman SV, Povsic TJ, Melton L, Barsness GW, Prather K, Heitner JF, Kilaru R, Gruberg L, Hasselblad V, Greenbaum AB, Patel M, Kim RJ, Talan M, Ferrucci L, Longo DL, Lakatta EG, Harrington RA; REVEAL Investigators. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA. 2011 May 11;305(18):1863-72. doi: 10.1001/jama.2011.592.
PMID: 21558517
citation: Ott I, Schulz S, Mehilli J, Fichtner S, Hadamitzky M, Hoppe K, Ibrahim T, Martinoff S, Massberg S, Laugwitz KL, Dirschinger J, Schwaiger M, Kastrati A, Schmig A; REVIVAL-3 Study Investigators. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. Circ Cardiovasc Interv. 2010 Oct;3(5):408-13. doi: 10.1161/CIRCINTERVENTIONS.109.904425. Epub 2010 Aug 24.
PMID: 20736448
citation: Vilarinho KA, de Oliveira PP, Saad MJ, Eghtesady P, Filho LM, Vieira RW, Petrucci O. Erythropoietin protects the systolic function of neonatal hearts against ischaemia/reperfusion injury. Eur J Cardiothorac Surg. 2013 Jan;43(1):156-62. doi: 10.1093/ejcts/ezs254. Epub 2012 May 7.
PMID: 22564802
citation: Watson AJ, Gao L, Sun L, Tsun J, Jabbour A, Ru Qiu M, Jansz PC, Hicks M, Macdonald PS. Enhanced preservation of the rat heart after prolonged hypothermic ischemia with erythropoietin-supplemented Celsior solution. J Heart Lung Transplant. 2013 Jun;32(6):633-40. doi: 10.1016/j.healun.2013.03.014.
PMID: 23701853
citation: Lu MJ, Chen YS, Huang HS, Ma MC. Erythropoietin alleviates post-ischemic injury of rat hearts by attenuating nitrosative stress. Life Sci. 2012 May 22;90(19-20):776-84. doi: 10.1016/j.lfs.2012.04.012. Epub 2012 Apr 12.
PMID: 22521289
citation: Xu X, Cao Z, Cao B, Li J, Guo L, Que L, Ha T, Chen Q, Li C, Li Y. Carbamylated erythropoietin protects the myocardium from acute ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Surgery. 2009 Sep;146(3):506-14. doi: 10.1016/j.surg.2009.03.022. Epub 2009 Jun 9.
PMID: 19715808
citation: Prunier F, Biere L, Gilard M, Boschat J, Mouquet F, Bauchart JJ, Charbonnier B, Genee O, Guerin P, Warin-Fresse K, Durand E, Lafont A, Christiaens L, Abi-Khalil W, Delepine S, Benard T, Furber A. Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial. Am Heart J. 2012 Feb;163(2):200-7.e1. doi: 10.1016/j.ahj.2011.11.005.
PMID: 22305837
citation: Voors AA, Belonje AM, Zijlstra F, Hillege HL, Anker SD, Slart RH, Tio RA, van 't Hof A, Jukema JW, Peels HO, Henriques JP, Ten Berg JM, Vos J, van Gilst WH, van Veldhuisen DJ; HEBE III Investigators. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J. 2010 Nov;31(21):2593-600. doi: 10.1093/eurheartj/ehq304. Epub 2010 Aug 29.
PMID: 20802250
citation: Momeni M, Liistro G, Baele P, Matta A, Kahn D, Van Dyck M, De Kock M, De Kerchove L, Glineur D, Thiry D, Gregoire A, Jacquet LM, Laarbui F, Watremez C. An increase in endogenous erythropoietin concentrations has no cardioprotective effects in patients undergoing coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2012 Apr;26(2):251-7. doi: 10.1053/j.jvca.2011.07.034. Epub 2011 Oct 5.
PMID: 21975293
citation: Taniguchi N, Nakamura T, Sawada T, Matsubara K, Furukawa K, Hadase M, Nakahara Y, Nakamura T, Matsubara H. Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebo-controlled study. Circ J. 2010 Nov;74(11):2365-71. doi: 10.1253/circj.cj-10-0267. Epub 2010 Sep 8.
PMID: 20834185
citation: Bergmann MW, Haufe S, von Knobelsdorff-Brenkenhoff F, Mehling H, Wassmuth R, Munch I, Busjahn A, Schulz-Menger J, Jordan J, Luft FC, Dietz R. A pilot study of chronic, low-dose epoetin-beta following percutaneous coronary intervention suggests safety, feasibility, and efficacy in patients with symptomatic ischaemic heart failure. Eur J Heart Fail. 2011 May;13(5):560-8. doi: 10.1093/eurjhf/hfr002.
PMID: 21505058
citation: Ferrario M, Arbustini E, Massa M, Rosti V, Marziliano N, Raineri C, Campanelli R, Bertoletti A, De Ferrari GM, Klersy C, Angoli L, Bramucci E, Marinoni B, Ferlini M, Moretti E, Raisaro A, Repetto A, Schwartz PJ, Tavazzi L. High-dose erythropoietin in patients with acute myocardial infarction: a pilot, randomised, placebo-controlled study. Int J Cardiol. 2011 Feb 17;147(1):124-31. doi: 10.1016/j.ijcard.2009.10.028. Epub 2009 Nov 10.
PMID: 19906454
citation: Poulsen TD, Andersen LW, Steinbruchel D, Gotze JP, Jorgensen OS, Olsen NV. Two large preoperative doses of erythropoietin do not reduce the systemic inflammatory response to cardiac surgery. J Cardiothorac Vasc Anesth. 2009 Jun;23(3):316-23. doi: 10.1053/j.jvca.2008.08.018. Epub 2008 Oct 22.
PMID: 18948032
citation: Kagaya Y, Asaumi Y, Wang W, Takeda M, Nakano M, Satoh K, Fukumoto Y, Shimokawa H. Current perspectives on protective roles of erythropoietin in cardiovascular system: erythropoietin receptor as a novel therapeutic target. Tohoku J Exp Med. 2012 Jun;227(2):83-91. doi: 10.1620/tjem.227.83.
PMID: 22688525
citation: Gobe GC, Morais C, Vesey DA, Johnson DW. Use of high-dose erythropoietin for repair after injury: A comparison of outcomes in heart and kidney. J Nephropathol. 2013 Jul;2(3):154-65. doi: 10.12860/JNP.2013.27. Epub 2013 Jul 1.
PMID: 24475445
responsible party type: Principal Investigator
investigator affiliation: Shahid Beheshti University of Medical Sciences
investigator full name: Mahnoosh Foroughi
investigator title: Clinical Professor
mesh term: Reperfusion Injury
mesh term: Myocardial Reperfusion Injury
mesh term: Ischemia
mesh term: Wounds and Injuries
mesh term: Epoetin Alfa
sharing ipd: No